• Molecular NameAnastrozole
  • SynonymAnastrozol; anastrozole
  • Weight293.374
  • Drugbank_IDDB01217
  • ACS_NO120511-73-1
  • Show 2D model
  • LogP (experiment)4.501
  • LogP (predicted, AB/LogP v2.0)4.09
  • pkaN/A
  • LogD (pH=7, predicted)4.09
  • Solubility (experiment)0.5 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.43
  • LogSw (predicted, AB/LogsW2.0)0.02
  • Sw (mg/ml) (predicted, ACD/Labs)0.11
  • No.of HBond Donors0
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds6
  • TPSA78.29
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used to treat breast cancer after surgery and for metastases in post-menopausal women.
  • Absorption_value100.0
  • Absorption (description)Anastrozole is rapidly and almost completely absorbed after oral administration
  • Caco_2N/A
  • Bioavailability80.0
  • Protein binding40.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe drug undergoes metabolism in the liver by N-dealkylation, hydroxylation and glucuronidation. The main inactive metabolite is triazole.
  • Half life50 h
  • ExcretionThe metabolites are excreted mainly in urine; less than 11% is excreted unchanged. It is removed by dialysis.
  • Urinary Excretion<10
  • CleranceN/A
  • ToxicityIn rats, lethality is greater than 100 mg/kg.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A